Safe Threshold to Discontinue Phototherapy in Hemolytic Disease of Newborn
Hemolytic Disease of Newborn, Neonatal Hyperbilirubinemia
About this trial
This is an interventional prevention trial for Hemolytic Disease of Newborn focused on measuring Jaundice, Newborn, Hyperbilirubinemia, Rebound hyperbilirubinemia, Phototherapy, Hemolysis
Eligibility Criteria
Inclusion Criteria:
Healthy term and late-preterm neonates more than or equal 35 weeks gestation with hemolytic disease of newborn will be included. Enrolled infants should have evidence of hemolysis as defined by any of the following criteria:
- positive DAT and blood group iso-immunization (ABO / RH incompatibility);and /or
- HGB decline by 2g/dl within 24hour.
Exclusion Criteria:
- Major congenital abnormalities,
- Surgical problems,
- Direct hyperbilirubinemia
- Sepsis
Sites / Locations
- Madinah maternity and children's hospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Low-threshold group
High-threshold group
Neonates in the low-threshold group phototherapy will be stopped if TSB reached ˃100 µmol/L below the AAP phototherapy threshold.
Neonates in high-threshold group phototherapy will be ceased if TSB level is 50-100 µmol/L below the appropriate AAP phototherapy threshold.